Victimes de Médicaments : Y a t-il encore un Espoir?
La réalité reprend le dessus. Nous espérions que l’affaire du Mediator allait changer radicalement la gestion du risque médicamenteux. Le rejet par le Sénat du projet de loi sur la sécurité sanitaire du médicament montre les limites d’une ambition avortée.
DES daughters are at 368% higher risk for premature births
No mention of DES there, but could DES be responsible for the high percentage of mothers who give birth before their children are due in the U.S.A.? DES daughters fortunate enough to get pregnant are at 368 percent higher risk for premature births …
Diethylstilbestrol or DES was sold under many names including Distilbène®, Stilboestrol-Borne®, Benzestrol®, Chlorotrianisene®, Estrobene® and Estrosyn® to name just a few. Many companies manufactured and marketed this drug under more than 200 different brand names.
Drugmakers once touted nerve growth factor inhibitors as a potential breakthrough
The power of big pharma and big money!
Drug makers often abandon research on experimental drugs that appear to have safety issues but with more than 50 million U.S. adults diagnosed with arthritis the potential multibillion dollar market opportunity may be too big to ignore …
Here we go again !!!